Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...
The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.
GlobalData on MSN11d
FDA approves AbbVie’s Emblaveo for intra-abdominal infectionsAbbVie has received US FDA approval for Emblaveo to be used in conjunction with metronidazole for individuals with cIAI.
AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...
Approval of this indication is based on limited clinical safety and efficacy data for Emblaveo. In REVISIT, study participants with cIAI (n=312) were randomly assigned 2:1 to receive aztreonam ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...
The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.
Addresses the significant threat of antimicrobial resistance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback